

## NeuroMetrix Reports Milestone for DPNCheck® Testing within the Medicare Advantage Market

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. ([NURO](#)), an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders, today reported that over 200,000 Medicare Advantage members have been assessed for diabetic neuropathy with the DPNCheck device.

DPNCheck provides Medicare Advantage organizations with a clinically superior method of detecting diabetic neuropathy compared to the traditional monofilament test that's typically used in the primary care setting. This quantitative test measures standard nerve conduction parameters providing physicians with objective data that helps determine if the individual has diabetic neuropathy.

"DPNCheck represents a significant clinical advance for Medicare Advantage organizations," said Michael MacDonald, NeuroMetrix Senior VP of Commercial Operations. "These organizations depend on reliable diagnostic data to accurately risk assess their members and then proactively manage those with neuropathy to prevent debilitating and costly complications such as foot ulcers and falls."

### About DPNCheck

DPNCheck is a quantitative nerve conduction test that is used by physicians and health care professionals to evaluate systemic neuropathies such as diabetic peripheral neuropathy, or DPN. It is designed to be used at the point-of-care to objectively detect, stage, and monitor DPN. The device measures nerve conduction velocity and response amplitude of the sural nerve, a nerve in the lower leg and ankle. These parameters are recognized as sensitive and specific biomarkers of DPN.

### About NeuroMetrix

NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit [www.NeuroMetrix.com](http://www.NeuroMetrix.com).

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20150827005194/en/>

NeuroMetrix, Inc.  
Thomas T. Higgins, 781-314-2761  
SVP and Chief Financial Officer  
[neurometrix.ir@neurometrix.com](mailto:neurometrix.ir@neurometrix.com)

Source: NeuroMetrix, Inc.

News Provided by Acquire Media